LY 3381916

Drug Profile

LY 3381916

Alternative Names: LY3381916

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 17 Nov 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Belgium and USA (PO) (NCT03343613)
  • 17 Nov 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Belgium and USA (PO) (NCT03343613)
  • 15 Nov 2017 Eli Lilly plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) (NCT03343613)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top